I'm guessing some investors liked the ASH abstracts released yesterday. More strong stock action today on fairly low volume.
Clearly, GILD thinks it'll do even better. I've seen peak sales estimates for IMMU's Trodelvy as high as $4B. Consider that 20 average revenue estimates for SGEN are $1.47B and $1.77B, for REGN (MC $64B) they are $8.15B and $9.5B), for VRTX (Market cap $69B) $5.99B and $6.8B. If you think a buyout at below $400 ($70B market cap) would be too low today, I just feel it is not realistic. If a buyout happens, I still think it is likely to be in 2021 with MRK now being the most likely buyer.
